(Q45252401)

11 December 2017

title

Hepatitis B virus reactivation and alemtuzumab therapy (English)

1 reference

11 December 2017

1 reference

1 reference

7

1 reference

11 December 2017

9

1 reference

11 December 2017

5

Emanuele Ammatuna

1 reference

11 December 2017

Emilio Iannitto

1

1 reference

11 December 2017

Viviana Minardi

2

1 reference

11 December 2017

Giuseppina Calvaruso

3

1 reference

11 December 2017

Antonino Mulè

4

1 reference

11 December 2017

Rosa Di Trapani

6

1 reference

11 December 2017

Vincenzo Abbadessa

8

1 reference

11 December 2017

Rosa Di Stefano

10

1 reference

11 December 2017

publication date

1 March 2005

1 reference

European Journal of Haematology

11 December 2017

published in

1 reference

11 December 2017

volume

74

1 reference

11 December 2017

issue

3

1 reference

11 December 2017

page(s)

254-258

1 reference

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00375.X

Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00375.X

Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00375.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00375.X

Clinical virology of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00375.X

Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00375.X

Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00375.X

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00375.X

Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00375.X

Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00375.X

10.1111/J.1600-0609.2004.00375.X

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference